

UBS (CH) Institutional Fund – Equities Switzerland Passive Large II I-X

Portrait

- Regulation / Supervision: CISA / FINMA (funds for qualified investors)
- Authorised investors: pension funds, insurance companies, family offices and institutional investors under CISA
- Investment: Equity securities issued by major Swiss companies listed in the SPI 20®
- No investments in securities on the recommendation list for the exclusion of SVVK-ASIR (www.svvk-asir.ch) and controversial weapons.
- Convertible and warrant bonds: none
- Portfolio is passively managed and aims to replicate the gross performance of the benchmark (before fees)
- Securities lending: not permitted
- Use of derivatives: permitted under BVV2
- All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.

Securities no.	4,616,414
ISIN	CH0046164148
Reuters symbol	_
Bloomberg Ticker	UESWPLX SW
Currency of account	CHF
Issue/redemption	daily
Dilution Levy in Favour of the Fund in/out	0.01%/0.01%
Flat fee	0.000%
TER (as of 31.10.2024)	0.01%
Benchmark	SPI 20 (Total Return)

Current data

Net asset value 31.7.2025 - high last 12 months - low last 12 months Assets of the unit class in m	CHF CHF CHF	3,686.09 3,979.42 3,332.42 869.32
Fund assets in m	CHF	888.99

Key risk figures (annualised)

	2 years	3 years
Tracking error	0.01%	0.02%
Beta	1.00	1.00
Correlation	1.00	1.00
Total risk	11.23%	11.30%
Sharpe ratio	0.34	0.30
Risk-free rate (2 years) = 1.12%		

The statistical ratios were calculated on the basis of logarithmic returns.

Sectors (in %)

	Fund	Benchmark
Materials and supplies	9.42	9.42
Industrials	9.32	9.32
Consumer discretionary	5.82	5.82
Consumer staples	14.87	14.87
Health care	36.85	36.83
Financial system	21.53	21.53
IT	1.04	1.04
Telecommunication services	1.16	1.17
Total	100.00	100.00

Performance (in %, net of fees)

	Fund	Benchmark
08.2024	0.98	0.99
09.2024	-2.12	-2.12
10.2024	-3.09	-3.09
11.2024	-0.26	-0.26
12.2024	-1.39	-1.39
01.2025	8.58	8.59
02.2025	3.23	3.23
03.2025	-1.90	-1.90
04.2025	-2.49	-2.48
05.2025	1.26	1.26
06.2025	-2.48	-2.48
07.2025	-0.72	-0.72
2025 YTD	5.12	5.14
2024	6.74	6.77
2023	5.91	5.96
2022	-14.59	-14.55
2021	23.70	23.70
2020	2.74	2.79
Ø p.a. 2 years	4.92	4.95
Ø p.a. 3 years	4.40	4.44
since end of fund launch month		
10.2008	199.47	200.24

Indexed performance



UBS (CH) Institutional Fund – Equities Switzerland Passive Large II I-X
 SPI 20 (Total Return)

Past performance is no guarantee of future trends. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units.

10 largest positions according to issuers (in %)

	Fund	Benchmark
Novartis AG	15.02	15.01
Nestle SA	14.87	14.87
Roche Holding AG	14.66	14.66
UBS Group AG	7.43	0.00
ABB	6.86	6.86
Top 5	58.84	51.40
Zurich Insurance Group AG	6.61	6.61
Cie Financiere Richemont SA	5.82	5.82
Swiss Re AG	3.50	3.50
Lonza	3.35	3.35
Alcon AG	2.91	2.91
Top 10	81.03	73.59

UBS (CH) Institutional Fund – Equities Switzerland Passive Large II I-X

For marketing and information purposes by UBS. For professional clients / qualified investors only. UBS funds under Swiss law. Arrangements for marketing fund units mentioned in this document may be terminated at the initiative of the management company of the fund(s). Before investing in a product please read the latest prospectus, and key information document or similar legal documentation carefully and thoroughly. Any decision to invest should take into account all the characteristics or objectives of the product as described in its prospectus, or similar legal documentation. Investors are acquiring units or shares in a fund, and not in a given underlying asset such as building or shares of a company. The information and opinions contained in this document have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is quaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document. Any Index referenced in this document have been compiled or arrived at based funds and promote herein may not be eligible for sale of any of the securities or other financial instruments mentioned in this document. Units of UBS Group may have a position in and may make a purchase and / or sale of any of the securities or other financial instruments mentioned in this document. Units of UBS funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors and may not be offered, sold or delivered in the United States. The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The calculated performance takes on the product level into consideration (ongoing costs). The entry and exit costs, which would have a negative impact on the performance, are not taken into consideration. If whole